Today we reported financial results and provided highlights of recent business updates for the third quarter of 2026.
Read more: bit.ly/4iKkp9G
77
Heading to #elevatefall2026 to connect with the PAs and NPs on the frontlines with patients, helping them manage chronic diseases like plaque psoriasis.
37
New Phase 3 data for envudeucitinib announced at #FallClinical2026 showed rapid, durable reductions in PsO disease burden across scalp, itch, and quality-of-life measures, building on the high‑threshold skin clearance observed in ONWARD. NDA submission on track for 4Q 2026. Learn more: bit.ly/4rVOwPu
69
We’re in Las Vegas for #FallClinical2026! Sharing new Phase 3 data on envudeucitinib, our investigational next‑gen TYK2i for plaque #psoriasis. Want to learn more? Explore our posters in the exhibit hall and stop by our tabletop in the Cristal Ballroom to meet the team.
62
UPDATED: Alumis is in Vienna for #EADV2026. Stop by Booth X2004 to meet the team and learn more about envudeucitinib, our investigational next‑gen TYK2i for plaque #psoriasis. Explore our #EADVCongress e‑posters here: bit.ly/4xXDTNN
94
Alumis is in Vienna for #EADV2026. Stop by Booth 5712 to meet the team and learn more about envudeucitinib, our investigational next‑gen TYK2i for plaque #psoriasis.
Explore our #EADVCongress e‑posters here: bit.ly/4xXDTNN
88
Members of our executive committee will be on the road in September, with investor meetings and conference participation in Boston and New York. Full schedule: bit.ly/4gQRSOY
1
106
Today we announced our Q2 2026 financial results and upcoming milestones for envudeucitinib - potentially pivotal Phase 2b topline results in SLE expected in Q3 and an NDA submission for moderate-to-severe plaque psoriasis planned for Q4. bit.ly/4x1STKM
1
113
Today we announced our Q2 2026 financial results and upcoming milestones for envudeucitinib - potentially pivotal Phase 2b topline results in SLE expected in Q3 and an NDA submission for moderate-to-severe plaque psoriasis planned for Q4. bit.ly/4x1STKM
2
98
ONWARD3 LTE data for envudeucitinib are in: 54% achieved PASI 100—the highest reported among oral PsO therapies, durable skin clearance, and long‑term safety data remained consistent with ONWARD 1/2. bit.ly/3S50Srg
Today we announced our Q1 2026 financial results, along with recent achievements and key upcoming milestones. Learn more: bit.ly/4noy48a
1
87
Catch our poster on 5/14 at #SIDChicago26, where we’ll present biomarker data on envudeucitinib, an investigational oral treatment for PsO. Learn more: bit.ly/4en0JIq
1
117
New manuscript in Dermatology and Therapy explores how envudeucitinib’s TYK2 MOA and P2 data make it a promising next-gen oral therapeutic candidate for PsO. bit.ly/4duNDsf
2
119
Late-breaker P3 data of our investigational TYK2i at #AAD2026 reinforced its potential as a leading oral therapy for psoriasis. Investor webcast 3/29 at 5pm MDT. bit.ly/EnvuAAD
2
194
Today we reported year-end 2025 financial results and a summary of recent achievements and upcoming milestones for envudeucitinib in plaque psoriasis and lupus: bit.ly/4bzoTwp
2
94














